0001558370-24-009198.txt : 20240614 0001558370-24-009198.hdr.sgml : 20240614 20240614161509 ACCESSION NUMBER: 0001558370-24-009198 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240613 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevation Oncology, Inc. CENTRAL INDEX KEY: 0001783032 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 841771427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40523 FILM NUMBER: 241044955 BUSINESS ADDRESS: STREET 1: 101 FEDERAL STREET STREET 2: SUITE 1900 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7163711125 MAIL ADDRESS: STREET 1: 101 FEDERAL STREET STREET 2: SUITE 1900 CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: 14ner Oncology, Inc. DATE OF NAME CHANGE: 20190719 8-K 1 elev-20240613x8k.htm 8-K
0001783032false00017830322024-06-132024-06-13

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2024

Elevation Oncology, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware

001-40523

84-1771427

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

101 Federal Street, Suite 1900

Boston, Massachusetts

(Address of Principal Executive Offices)

02110

(Zip Code)

​

(716) 371-1125

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ELEV

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 13, 2024, Elevation Oncology, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for each proposal considered at the Annual Meeting are set forth below. For more information on the proposals, see the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2024.

Proposal 1: By the following vote, the following two persons were elected to serve as Class III directors until the Company’s 2027 annual meeting of stockholders and until such time as their successor has been duly elected and qualified or until their earlier resignation or removal:

​

​

​

​

​

​

​

​

​

​

​

​

Nominee

Shares For

Shares Withheld

Broker Non-Votes

Timothy P. Clackson, Ph.D.

24,340,761

7,849,933

9,558,342

Alan B. Sandler, M.D.

32,173,851

16,843

9,558,342

Proposal 2: By the following vote, the stockholders ratified the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024:

​

Hares For

Shares For

Shares Against

Shares Abstaining

Broker Non-Votes

41,728,366

20,366

304

0

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

Elevation Oncology, Inc.

​

Date: June 14, 2024

​

By:

/s/ Tammy Furlong

​

​

Tammy Furlong

​

​

Chief Financial Officer

​

​

​

 EX-101.SCH 2 elev-20240613.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 elev-20240613_def.xml EX-101.DEF EX-101.LAB 4 elev-20240613_lab.xml EX-101.LAB EX-101.PRE 5 elev-20240613_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 13, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Jun. 13, 2024
Entity Registrant Name Elevation Oncology, Inc.
Entity File Number 001-40523
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 84-1771427
Entity Address, Address Line One 101 Federal Street
Entity Address, Address Line Two Suite 1900
Entity Address, City or Town Boston
Entity Address State Or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 716
Local Phone Number 371-1125
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ELEV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001783032
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://elevationoncology.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports elev-20240613.xsd elev-20240613_def.xml elev-20240613_lab.xml elev-20240613_pre.xml elev-20240613x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "elev-20240613x8k.htm": { "nsprefix": "elev", "nsuri": "http://elevationoncology.com/20240613", "dts": { "schema": { "local": [ "elev-20240613.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "elev-20240613_def.xml" ] }, "labelLink": { "local": [ "elev-20240613_lab.xml" ] }, "presentationLink": { "local": [ "elev-20240613_pre.xml" ] }, "inline": { "local": [ "elev-20240613x8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_6_13_2024_To_6_13_2024__xYAu7u5yU6bzBoLV1kqZw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "elev-20240613x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_13_2024_To_6_13_2024__xYAu7u5yU6bzBoLV1kqZw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "elev-20240613x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001558370-24-009198-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-009198-xbrl.zip M4$L#!!0 ( .2!SEC%F880RP, $D/ 1 96QE=BTR,#(T,#8Q,RYX M\.^KJ_:[DZ(DJS:2X#M(H"1 51!9,K*^#VJS" M7X+WB[=OKGX*P\>;ASM42%*75!A$%,6&%FC+S 9]D56%!;JG2C'.T8UBQ9HB ME";1+,JB"Q2&"P=Q@S682($<5A:E7O"Q19-BCF9QFL=9DOT,]O/\W3Q]A_Z\ M]XKW0&W%3FKN=#'79$-+C Q6:VI^QR75%2;T.M@84\WCF'+ZA VX+<%?+M?/ M$9&E0TMF:1X@;(QBR]K0WZ0J;^D*U]Q 2,0_->:. D2*4QN+GL*!&$(K]!RH M='MNM]MHFT=2K6&C)(T?[^\^.Y9>N=;A&N.J,UAAO73JK<#RR[VRHJL>\FZI MN,>>Q2#UBEJ9T#Q75+_$[40]9(M4F$[[$/@B;H0'C)7D0]!>TD?FHY3S^/&. MB:]>4V!&=)^"IB1:RZ?8B7JPUHT1&IVH9U ;-4KD,@:I5^1 :8*R%2_A5!\0 M&:30VYS42D&5/0][YZ4]$[HCFV%U*SD*\3'E]LBEEY>7L9-V;!D9!@5!#U/0 MM:W/B9#9$,>M6N>GK(518VXVPGY6]-@Y]9)^UDVE1OB#I*=Z1C7[GP\SV\\:\ M,.HHMCV6((ZMV.)E89*'>=I9TDI1(-0FY@8"&D<9&S2WZQJIA8R68%UFSYS"WQ+Q M9%_^ M>OAT(I7.S]MV(<<:H)RA;=BM<:LR84@P)S5_O=V> MUJA9N^CS\@VRQ33A4M>*?H;"+; J( L?:VUD^6'']*TL,1-M']%MVEYE,I$_ M:-.)RU\'"!\>$P$H:E"1A44-+O+ /W8J_;A]H"OD)MG<-JWK0+.RXK:[NK6- MNQG9[(:^B_X-KD;0$[R*A9_HU^X,'$>GW=A#8$5>H+R8M B*ZH,@]&UORO$ MW\HKB.=KO>JGX#OTB>/E:WT"$\K_%W>NXJ,AT"[T1H4;%."75 :)%S\:(Y.L M^3VYD\3!--IZ3-V^V CE$6S5DIO>=>H.,K3UH(G]ZNXZH5T*TPRN!F>S&/YS M.'-_;V WOOAOC@]>:\8B?\K2?>N.2',2&K#%OU!+ P04 " #D@G&YR@5Z!&VXDKTHB5L1 IDIQN6L%Q5VBL^BR_ZWHXOO&-]?W8P04UF1@[0H MTT M,+3D=H[NU&)!)1J#UEP(=*4YFP%"22ONQNWX!&'<+R&NJ'$I2J(2JQTG M8>"Z0E,R15V2=$B[U?[A\M/.:9JI4E7 MAO>BN;6+E)#E'2;S2&GF$MCJC_A%"ZTIK)> &ILC__[GY5:>!@,>R;/+NA.@N&JL^F)U\[,#F-H=!JX?_* M>A P,"55/%ER!AI+JK5:@M[-V+2T:UZ$UC6>)\15PUE/SG"2X':Y=HY?4"%V] 'D%LBX1SR MR4<7P&ZMF[B?%SIWFG163 #793B@W)WH!UT,ZUW]-:LA8#<$NSXNN3_31JY9 M,7A-7W;HK2W!RH)DP.I>;CVG.^A;+831,[)K!'#DT-$:'GE\M"9 -8.W%8P) ME6T0"G_I*;U=1!,FQD 6S]0C8<#]+=SQ'_Y<7I_)KO'P4SJ93P/&-!@#IOJX M<_A>3H 6= *B%[V?\)"\<+]?"OEJFPW.X<;9U'"V%;/3S,ZH#?W/ZV^@-YVX MO1$0IUKE_UE0]8: PCAXM?"DM+X9JJWXF;T:? ='Z3Z*W6,3O:I4:7<7NG=L MV+)DQYYUST.R\3[L_P-02P,$% @ Y('.6'6NG;CP!0 ]44 !4 !E M;&5V+3(P,C0P-C$S7VQA8BYX;6S5F^%OXC88QK]7VO_PCGW9I LIL+M;4PD!A+L0*%DYLM=BA\_?E[SJ['35&1\ZOU4^M'ZXN/[1<;[=?7V @/JS"2(< M?(8\C@*88SZ&/IU./0*/B#$A""<1> M]6I--;13-TJ:\,ZM-=SZ9?U7T;_9>-^LO8?NHQ(^BFA#O%,98O)O4_XS$"." MJ)%$S46$;RICSJ=-UYW/Y]5YHTK92/2_K+G?'A]Z_AA-/ >3B'O$1Q40^F84 MO_A ?8_'$[31?3%@H3)HN*NQC KYDZ-DCGS)J=6=1JVZB()*&E$V[S&(DLO6 M@*\Z;(K?NDGC2KIEG99?N[JZY(2\< M>2$G[2?QP_#B+./)\KISC^3477+B=CKQEV56CI==Z8]<,C['W_P.C6*A1AZ-)M-\L;,K/"LJM M.@O 7&G/!L[MQ*\+J/2'>( 2*>T+QX+RTV;[*=RL(T^=;+.;LDS"HZF2;N41 MU$4,T^">!!_% :&@QKS.?J:TE>7ARHCLIDP?]6C<$ENQ!PQ &I^>O&2W^16- ML-QA$O[%F^C ,\CLY:ZH+H6=3F,G=85)#X4N/6BL74':EH7<)QRB+[/) #%C MO1F)[:AMUY/%;-UN,V*:E$?B)1TAL2P+K0[Q*9M2%N\%>URLHVTZ(YPMVS0P M+VZ[>MD.X%Y59YDL[&(SIOL%/Y+T9"K;XO*)]>F<[)J%C/),B-RN3LOC6G8&-&K"OA:+TEKN,J5YR1S& M.]PGUF7T&1/??%(RRL^$2$.=6BQSVC-@TY3X=0!-CT%/#-0 )4/:I1'WPK_P MM/ P;Q"?":#:&K5X9I1G *<^[VNMG8D["/N2#N=RL;YER#.PF&NVESY=':NG M<3;:["1,F_!0IN+/7^E6$D+R<;NP.Z;$?#=<([$7)5,]"J=\NYU(&5,>BE5L M"+%C:3=D_F28 MNQX-L8\Y)J-'L5=DV-.5K!792YRY)H7;ML).U@IR'@K:VA*4Y^DIZS(DP4;B M;8L?^Y%/:[.GX5#[$5HHMI>ZW34J^LQ*.RG<(^^A- IKQ]_PAL0<8O?2N>Q$ MT0RQ%]&IZW(VC!KK-9"ZI3\+7LVI7XW:9(B2X>TA?R9V#E8?VKEV.^$SICP4MM@%Z!!J]9\'OX#R/SU??>;);]OUEI,!U56:;[>7 M+&TE"JM,HYU,Z2,>#%3B!HE=>>O4_<(?B\3(\-BJ068O545UY=>L38V=C!4F M/?BPD9J"]36I[ =RCRNP?(K12.W'< M)_"1?XI0YI"X0VI?&IT+L1"3",L;/N ' M<=6Z4*^D?5O_ 5!+ P04 " #D@$X0"OQ6I]5N72#7O$0=I^UZ6G[P7$59Y@K:Z MKZ>260>A]W:M6@OSR[5FKCGE!FTW#%KK+'9*B::YP46LN6FE']AOQ5+8'_@O MVJ2D[V0T29EQE9];2#+K.X215]< \#M! M: +YY7,Y/NSW@,=W7%&U&?&9D$F>1@<9_[\]C=ZD&#]YD]!CCXGYIA6)Q#-6 M7C.'>7R-,N?E ::29-I9WOM>MY51F2O^0%%;V2-K17A,XK>S5)E+^;[?]9&+ MK*/M0\QC5'A%?R]6$ZF.E8EH1PHSHUG(79+&6Z;=Y:XR$K7FXM6+"36W5V@. M#.8"L?[Q,A1ZSAA,,R5QI*PGAJ>$]9V#]I>@3/L_),9F;*(]5FC9;G[IA%<7 M83>X\,-+OWM^&72NWK5M#XJ!W-6)961=Z\.=<7)(H+3P4BRU/S=:4/8&?B9% M4I.C\GJBH6PA8R+UG.V@9:;5B-3HQLQ!.HZ9GHE)?%\DH59G+C+/U+\#:$PD M%?I.B3_KR?X#4CMV )$=UU^R:__WV14ST!.94Q,U5]]P4H6NR@P0N<;R2W A M%'!?*"/?ELF4R%IH[R;@@!V17L(ZAP)KI!<:,A4RS_&S3C49BB57$ MRO!(!"7!+C""^0K@48ZE>*5%)>M#C'OF4%DV"<,^_OO B(Y%IC#[@Z8?+FJK MC*'2/!Z$90F@EF.FF8$DN(;>=C,@7D=E6T( *C9FMX*-%X+7/_COFP BU4BZ MI06@3/.[I$H1/A1)LN3E@U%6@:S2#A"WYOHM/ !EFV?!:$05Y?,'_8(^F6%H#" MRT1B\];0\R:9BJJ_P9UV0)R.Z[:0 -16[*"[6T<+S.>D9C>WR@P0LL;R[38\ MF!K*74+D7(_&7Z58J86>_5/,-[5%E$IK0!Q/C<+B!%!&*4-;Z]F%9]3(+%X: MJ6=Y8 H/9+,0+$4 I98BKJ%.C,1LI!=>ZZ^D_G; 6VG'1"LX[HMI!]98;GV]M^IO3F[]HJ<<=8R(3<(,(YG(>(,BHJ E_$+JY,T$ D)YB+@KS_5G03" M1045=6:8M?:6I#N=[JJGJZNKJBN[_QWV+'1/7,]T[.]?1%[X@HBM.X9IM[]_ M*=2+Y?*7_^[]:_?_. Z9U_NU"C(@1VT>Z2[!/##0P_4X>-9Q^']OHA+BN M:5EHWS6--HD>$04^PTM\&G%)^Z]J1-TY&BH?)!' M1$AGE+0F<(*F&YRBY"0.MXC,22U!-H2TK&(V/NX*L='F.?D!%CBN3-H<\!M:9> M%E//M*'SA+(IY;O8]EJ.VV,M0BMBFA.RG"PFVEE,L^<:D3@I,VGD,;H#\"8- MQ=5=TGJ43YD4E";I;C[!TC$=]W8[!!M[NSWB8T2K<^0N,(&FNF/[,,\X?]0' M:D=7W[=\,O13##NIO5W?]"VRMYN*_X9-:8XQVMLUS'OD^2.+?-_J8;=MVISO M]/.RT/>_P4M34#Q5QS"]OH5'>> =H17,89ZV1MSPIVD8Q&8_H<(I2 #7U,-. M#?T:)6K@][NCUP2#0C<-13JC?=/N: MKM9.1R?G39EVM(4MC\SU,35-8$ 1<4$($V]OET[EO,>F'G0:L:F=[S 4TLG& MQ7.+'WK&5E1, ?-]RS-[?8M0D*1FVF27GA.X[(H!-1\1AHWAA82)FR*,C?&5 M:=#KEDEP=NS1?G)"AA/E M^+E)V;B;QB-5XY+X.GY):HI4,5W'A$PE9LS<[.KA(3=\ [\]8!\K2_?6&W/?"!Y$=Z< M[ M/15(\>AB*[_18G?@6%5OTFE*=PY;9MO,ZP("XWS3'!7)/GADBS[%, _TC ML']Q.9-[]"TSQ:%8S$<2T:/Z2W)HK+,2%-Z;GJF9%N NFJ90_3__9"5!_K:; MHH\!8?IO01AIX2B7Z6;ZLW53F^^C2"''+@ST'?N.Z'^9\._\ M.)(=9ZV,U:!\T =QIH,N"4]=8:\#$\QW[!UTP!=YUO_'6]K:0Y*05G+C82;D MT,L'RF9_I*!$$SEQATY=859>B#G26R#?$L)O6DAJ6.^V72>P#8ZJI6X^%@!Q MBU38S#7'7LUGX%5APU*:AY9#D1)J23$[$ Y\9Z)4A?]_/08H#JG^.1YX]BE0 M2!$HA&5 L;5W>%8[08R3Z]20#J+-8H/IL'2E.<6NV]2%J]M&IM9V+P*G()Y5 MK_S# ^'\F1YGN>,0>;/:TP:)ZT;BD](HLQKP0(C62J<-5"M5SVJ-#Q7WTQVK M!JX78-M'OH/J1*)Z6WCZWL+=V4YUPC?7%1/C M:WY= BPT&'S?,H=^WH!.]*#-CH%'(^@)L1<)N"K;(Y3"G4-"TA4,8>"E3ZZ$ MTETK>ZU5+BK82,]+NB?)W+]H'APW%5%I0TUIMJ:1'3ZT15/5!?+SO#*HY]1JK4L-;G-O-S/W M^D5]7^]WC]4;KXM/S@KZ#:T9MYF4&3[6+#+F0FA) Y8N.^1?/PCB090A&*F M4%M,9+&-PJ7U!-&C=,^Z;O./5W,IA7,<*V'E=AQ0>ME;ZO3VD58$7QW5'0,,O8\ M6,%!3?&O3N]+Q7JKS+#HT M+0+M:\0=\Z/>T6XZ!:MGX>J4ZI#EKC3U.Y;M4?Z&R15N-.5N%$5145 M27V:/<_+/E#:WDWP":_5OID4HM:1,[]#7'04N*9GF,QL\H;6AM=V$S8&4[)S MHO\_/64FK'@' ?9J7A2=7L_T:.P+HF((A4A??:SO(!M>/=9RK8Y*O;[EC(C[ MB8 V+6K0J4"I]#%_VIF#81DR:U0HT, M@\&E7/KQHWK4/CXVL_K^O'GC29DM"B(Z)+"CPQ:J^RXA_D+9O4*+.^MWICQ& M'"E!G$!J[YN#_L\+X8=QW.M4G-NV8*UH;ZP')DAV,2<(ZS/^?"ZD%>'GF=MP M!G:"E/6C@ZHKWC7,TO'%?O^F_G-?D;.#U4BY[WA^O!Y^0FRMO ^)Z,76_C.W M"C5-%@LX)MKML5W\A1]Z2M=T[C-9\4JW;^_:JQ'M!'L>UCN!1WS?6R,$7[T4 M1=2@UL>J"X0P^R!.2D.B!W3;C,Y:L!P0[\U5CM1&U5\,RRK,-FS=F/W)KIB! MTM2K)^?MQH-8ZIW=N(+^8&E%8450"I(HKE,>OAJ,,&Q$Q[U([4@Q6^9;\?N/ MB4=ZA-7;:U_)Z7I3< F>P>E%YK9K&E>"5 JN^H>5Z^)#*==:<<51Q5>6LZ'OSWQ7='Y(:K?/-0@%NE3 D6;.>:-LP(JO1&%SLQ<_W@!=.KXJ-#O M6[ 8@:QYQXXQ2LM+4OH0-![BHE/F-'11=!FM'SO(;%%'H=TF!JI3S095L.=' M\0AO'0&2#.U*?T:Q*DQU:H;,Q0[1NRST!/=!8^R[)C4':*T1>S)ZP-& Z^&> M.@IU<2>.W@#:<1&V1W%9R['@Y?0YJL6:U"+BH6V/$/2#V&RW5[;AV2",[BGP M$A]V]VN>T2QR@6:SBFR(*@@T!>M-14D;S6PNBYN*)J0%"6.L&9E9U^+P=-BM M^QGG3"BV+HZYJZKQB\L5(EOOM+ORVJF/KGOZI5!/5\_KF6K3;)XL=('^].[D M0S^7*PBD?GYT^6MT?Y$=#,*3!-,UM?VSH7]UWM1*4J-T?W];TX[J9J&IC&N^ ME3/S44_EBUR3/<"O%3N-)%[-?J!;:]Z717WH:1CH)'B6_8*GR;:PPT'1UQ=[ M]*9&GE-Y2?S3AK[8WB5*?.8M0?&F&JT823EQG6$\LWMNS7$L#8/8\D%X)G6D M*]?T8+R4PP)8VAW!955#RL(4D6>*CX=167S@;,(9CK#BB&0%*[?0(R!)0%:XQD M?%TX-'-:I7HA7>I.(7N3R99^%:+@H0V2(^9-"(AZ$07G80SZ"B=*"21/Q0*/ M<:P(?%AS ^470+GJ$BJ3Z6%*=K2!*K/N6:N5=/SGI'.QTE6-"UP6[X/N7>?H M.!A$$6D;2$=,!$)R>H*2STII43$X:5O[NAS P[H;B+\>XF7/"XB[".@'VD$V M)_VZN>P&U9T%^A]N\UU@G)A8VQ(* M7&@M("XQIL@\/N##Y$ED/4C2>,H@H B"GE$DN:FKK593406QF9,RYUZE7NWIQ5!Z2\TA!GZII*8UVV\W=E+O%V]%)5S_I M25:QVTHA> R;2V88"/,X/%8:971X*CW!?.$: M5ZO<4Q;U!9K("IZ7!DU$$Y[9TSOHV0/ENH4];V7_>#2W_DC>/.WN>)8Y,]QP M,7,8A7K6]@M"$:*IOB'UL^ZOZ!@:PSV)%0G0, 8=$^Y,U)"%48%_NT1ZVH7_ M+INCA*TJU!Y'HJ0Q<3;>[32P'SC7SL5^R3P]JJ2[H_+MZ?6CEJKD?H;NIAQ: M[.C='=3'+KK'5D#0_PL\S7J$^C0]4H<=N7CICN VEZQ@ECK#_ MJR"?W>4N..&6N!G2"$0A]N\]B9)2I73Y%@#XHX7VQP-@UHQ"I?U\P&0L1>)- MY>20-O7>*(:6=BH/ET*F;0N-(.#<2O4\.MSZ)$8:L$\]Q9Z![U"=2A-T@MTN M\5&E4GP6.N]J%_A(2\ D_439-JB9A2!MA'06L@!5N[ H$W9J92:>P/00#( MW=I4;6J[SL#O4&M-G\888 \9I&7:X:'RT&\DI-%\!HY)X@T9;?_G'S&C?F.^ MH[@RO 8PT:?'T6D02FCRD31.6M#6HFP><:.A_6?R8*)=_@T#51[/[?&T-'N$ MC#'W/]"^&4:-QAW\P?I7#+N7B$3+W+E"U2J4JD+Q1'PHG)?O?AP=GK^!83/S MI&'SC9@VFV!O&0M>U,ERZXEIL /@7SBGS+GPG [,&&(1G2;SM1UF=PL\PFH! MJZ,@(!I7P';S*,RS2+G(WF6-Z,MI=F$6X6/#T*'$)2!8X#F8A]C6J1<,ZSH] M"TLKTY2J!G8-+PS_,1XS^LG;>*'1C_]$X!PVQI0)D\LDD'G?/')4T\E5A+KF MRW=':JW#Q5!:VB5+S5++*:>5K4?;)I :U>G+*91C[ MWF1ZD,#1A^1XGS*+_6BK33"+);#0&B2&^3;C0 M:HM;H'/DL37 (R_:@Z@Y7AXGG!FC66;*.4MMBQ*_)\;:95/FBNQDRTS*W.CF M&Z;,W1J[@&"544DV(S<508+_:;+2U+2,UB1J-JW+BF9(HKJ2$V9,FJWG#$ L M@2?=W'5,GW# 1YT R*C1/*:UM%[O]!.IP%:S#I=]TD-I7E#YQPR1GW\4DUF2 M_Z?%_K$CDUIT 'N!R?M)DE UY 3[,'\\JJ)@=.F$2>_B_2/Z"16AE%_KN1[: MNP4CB[?5\PG.SFPTE9=N!SV600QM4S6+RB%)^!9IV>Q*_/85=8AEL/Q<[!L/ M!=L.0*,[(82IZ(C4-8Q]I@O.O!^[,(UA;PV/@A+* L5Y&M&.>@Z4F/;XNP+4 MSDN?CYOV=A"-.:>W$@-FYSK8#M)DYP.A]G"$V)E+%A4 C="/+!BP':3[.^&; MJ!1H&'STC8W9G2&HNA/E-9$!@ :V]UW3"MN0,B%_WFI#*,SJ.M*3R'ETE:6_ M\Z8/(DY?-"VJ,9/$?+1TH?W13(@_,)CLS-SS!P[=1W@TK&( K!WO/^AA ^(" MU6%/4J1>IY \Y7(9&:8+=1P &-U&6 O9!B14@>(,'KT)/+TD/"E#PA:\ '#F M PWIVZ YTZ6W=.)Y !ZZ*]((L1$P>C3N'WWX#EH/D]9!M7%?3#=*@$DW/QZL M"!'DZ&7/N<=6?CW'Z&X#SS=;HYG?(U/7^ZG6J^!BTZM-KS:]VO1JTZL_KURRHF^']4<-;,7$I'>=S M[O=U1S9-&:UY*;/26?X>/$R6C!;[_"-_35Z#.@W+\>BV?T.."3FN3+]#;3<; MFD#AONMT:5()Q^:H]N$P);[@\-DIRAECI-&WC6\3LC5.6I M947O>O1[4M4.?\"_"!F?>^Q/(R5.D!$9225E1U:$'34C_NV44'>R2FXG)\M_ M.R%R.^ET%E AO4I O/L(I\QF*C\V%9HVS7N:Y\);4V*A8,$689]'=6P;%DU@ M=/)"B?"9V2E+.Z(J[V33+YKAGWED8@:F[(NFZV<>U6/3[P,]::]PCDC+.$>F M?!0T=HEY&*+,38YI^Z'SJ86*3L>ND0?;U+NH4JE&OHLY5PB=\GW"YOWTZ4H- MNIN,QFJ9;H^YW6@K]--9")ZB!0=$)S2G&9+%T#FU\6!L/!@?[\$0^L]FP/LY MV0MN3%B;X?U6P_L33%@;0\Y;DZ/0QJ;M^1N2)$BB>3X0!?JZHM%WY^EK-()H("X-U V_ M+JV1#K9:]$ D;8AE;8LJ=(A+ AN>825W.^8_FS)*9-AB]OO M@*C7VKB>D0Y+?VCKN3GX.<5\C F0Z/3F]RUIZUGH*SD^^PXNOF6M$^'9R/%' M"H)^G[@Z]BBD'CN.]BKSQ08PKY>/2Q/I&4&4>FONK06\!]@G^>BHI!)Z.U2G4P+W>"!T&KN50<_5&K+TY4J(/A=V7Q!L/KT%'-QR.XZ,?R3-)"A^.45>&7@=W=E+F^C Z? M)#O?,M]F??4F_I-"]FW,WTDK6F1XG@H*F[Y'30&RL-!J?N^8QN+L/).MM.88 M(_C3\7O6WO\ 4$L! A0#% @ Y('.6,69AA#+ P 20\ !$ M ( ! &5L978M,C R-# V,3,N>'-D4$L! A0#% @ Y('.6&G! M9P[I @ !@L !4 ( !^@, &5L978M,C R-# V,3-?9&5F M+GAM;%!+ 0(4 Q0 ( .2!SEAUKIVX\ 4 /5% 5 " M 18' !E;&5V+3(P,C0P-C$S7VQA8BYX;6Q02P$"% ,4 " #D@&UL4$L! A0#% @ Y('.6#$H\O>Y%@ '*8 !0 ( ! M$Q( &5L978M,C R-# V,3-X.&LN:'1M4$L%!@ % 4 2@$ /XH ! $! end XML 17 elev-20240613x8k_htm.xml IDEA: XBRL DOCUMENT 0001783032 2024-06-13 2024-06-13 0001783032 false 8-K 2024-06-13 Elevation Oncology, Inc. DE 001-40523 84-1771427 101 Federal Street Suite 1900 Boston MA 02110 716 371-1125 false false false false Common stock, par value $0.0001 per share ELEV NASDAQ true false